Category
Knee Osteoarthritis
Articles in this category

9/25/2024
Hip Fracture Risk in Elderly Adults: Evaluating Prediction Tools
π₯ Discover the latest insights on hip fracture risk prediction in elderly adults. Explore how FRAX, Garvan, and femoral neck BMD alone compare in predicting hip fractures. π©ΊπA recent study reveals that simple bone mineral density measurements can be as effective as complex tools. Clinicians should prioritise hip BMD, life expectancy, and patient preferences in treatment decisions.
Read more about the findings and their implications for clinical practice. #SyenzaNews #HipFractureRisk #HealthcareResearch #MedicalInsights
Read Article β
9/23/2024
The Economic Impact of Fall Prevention in Hospitals: Evaluating the Fall TIPS Program
π Did you know that hospital falls contribute to a staggering $17 billion in preventable costs annually? Our latest article explores the economic impact of the Fall TIPS Program, an evidence-based strategy proven to reduce falls and save healthcare systems millions. Discover how investing in fall prevention not only enhances patient safety but also supports financial sustainability in healthcare.
Read more here! π
#SyenzaNews #Healthcare #PatientSafety #FallPrevention #CostSavings #ValueBasedHealthcare #HealthInnovation
Read Article β
9/18/2024
Preventing Falls Among Older Adults: A Vital Healthcare Imperative
π§π΅ Falls among the elderly are a significant concern. Read our latest insight to explore the awareness and preventive measures of fall risks among older adults in Buraidah, Qassim. Discover key findings and strategies to reduce fall incidents.
#SyenzaNews #ElderlyCare #FallPrevention #HealthAwareness #PatientSafety
Let's work together to raise awareness and implement effective strategies to prevent falls among older adults.
Read Article β
8/22/2024
Enhancing Osteoarthritis Management Through Health Economics
πΆββοΈ Enhancing Osteoarthritis Management Through Health Economics πΆββοΈ
π Discover the importance of cost-effectiveness in osteoarthritis treatments! π Learn how health economics influences osteoarthritis (OA) management, optimising treatment strategies and resource allocation efficiency. π
#SyenzaNews #Osteoarthritis #CostEffectiveness #HealthEconomics #ValueBasedHealthcare
Read Article β
6/14/2024
The Economic Burden of Knee Arthroplasty Revisions: A Cost Analysis from TΓΌrkiye
π Uncover the escalating economic burden of knee arthroplasty revisions and the critical need for cost-effective healthcare solutions. Let's navigate the evolving landscape of orthopaedic care together! π©Ίπ‘
Discover how innovative healthcare solutions can alleviate the financial strains of knee arthroplasty revisions. Stay informed and join the conversation today!
#SyenzaNews #HealthcareEconomics #Orthopedics #MedicalResearch #HealthcareManagement #ResearchInsights ππ¬
Read Article β
6/6/2024
The Power of Real-World Evidence: Bringing Everyday Health Data to Drug Approvals
π Exciting news in the world of osteoporosis treatment! π Discover how Real-World Evidence (RWE) played a crucial role in the approval of abaloparatide (Eladynos) in the EU. This case study highlights the evolving acceptance of RWE in regulatory decisions, ensuring patient safety and fostering innovation. ππ¬ #Osteoporosis #RealWorldEvidence #Pharma #RegulatoryAffairs #Healthcare
Read Article β
4/4/2024
The Cost-Effectiveness of GaitSmart Rehabilitation Programme
Discover the cost-effectiveness of the #GaitSmart Rehabilitation Programme. This innovative solution for gait and mobility issues is showing promising results in cost savings. Read our full article for more insights. #HealthcareInnovation #CostEffectiveHealthcare ππ©ββοΈπ°
Read Article β
4/21/2023
Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by Β£1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Read Article β


